MetLife Investment Management LLC Boosts Stake in Eli Lilly and Company (NYSE:LLY)

MetLife Investment Management LLC boosted its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 0.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 244,080 shares of the company's stock after purchasing an additional 2,280 shares during the quarter. Eli Lilly and Company comprises 1.0% of MetLife Investment Management LLC's investment portfolio, making the stock its 12th biggest position. MetLife Investment Management LLC's holdings in Eli Lilly and Company were worth $188,430,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Highline Wealth Partners LLC lifted its stake in Eli Lilly and Company by 80.0% in the fourth quarter. Highline Wealth Partners LLC now owns 45 shares of the company's stock worth $35,000 after purchasing an additional 20 shares during the last quarter. FPC Investment Advisory Inc. lifted its stake in shares of Eli Lilly and Company by 358.3% in the 4th quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock valued at $45,000 after purchasing an additional 43 shares during the period. Prudent Man Investment Management Inc. purchased a new position in Eli Lilly and Company during the fourth quarter valued at $48,000. Compass Financial Services Inc bought a new stake in Eli Lilly and Company during the fourth quarter worth about $50,000. Finally, Fiduciary Advisors Inc. purchased a new stake in shares of Eli Lilly and Company in the 4th quarter worth approximately $58,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Trading Up 0.0 %

NYSE:LLY traded up $0.16 during mid-day trading on Wednesday, hitting $827.70. 1,760,750 shares of the stock traded hands, compared to its average volume of 3,423,500. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. Eli Lilly and Company has a 52 week low of $677.09 and a 52 week high of $972.53. The stock has a market capitalization of $784.80 billion, a price-to-earnings ratio of 70.68, a PEG ratio of 1.40 and a beta of 0.51. The firm's 50 day moving average is $827.10 and its two-hundred day moving average is $818.99.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts' consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. On average, equities research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of research analyst reports. Leerink Partners set a $950.00 target price on Eli Lilly and Company in a report on Friday, January 17th. Wells Fargo & Company lifted their price objective on Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. Guggenheim cut their price target on Eli Lilly and Company from $973.00 to $928.00 and set a "buy" rating for the company in a research note on Monday, April 14th. Cantor Fitzgerald assumed coverage on shares of Eli Lilly and Company in a research note on Tuesday. They issued an "overweight" rating and a $975.00 price objective on the stock. Finally, The Goldman Sachs Group raised Eli Lilly and Company from a "neutral" rating to a "buy" rating and decreased their target price for the stock from $892.00 to $888.00 in a report on Tuesday, April 8th. Two analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $1,017.00.

Insider Buying and Selling

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the firm's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the transaction, the chief accounting officer now directly owns 5,840 shares in the company, valued at $4,778,521.60. This trade represents a 14.62 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.